Answers are grounded in this paper and cite their sources.
Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials.gov number, NCT01245062.).
No takes yet. Share an insight, caveat, or question.
Flaherty et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: